[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 49,407 Class A ordinary shares on 08/12/2025, with an aggregate market value of $1,600,641.00. The shares represent part of the issuer's 43,472,928 outstanding shares and are to be sold on NASDAQ through Charles Schwab & Co., Inc.. The securities were acquired the same day via an employee stock option exercise and settled by a broker payment for cashless exercise. The filer reported "Nothing to Report" for sales in the past three months and included the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider exercise-and-sale; small relative size versus outstanding shares suggests limited market impact.

The Form 144 documents an insider exercise of employee stock options and an immediate cashless sale of 49,407 shares for $1,600,641, executed through Charles Schwab on 08/12/2025. Against 43,472,928 outstanding shares, the position equals roughly 0.11% of the share count, indicating the transaction is unlikely to be material to valuation or share supply. No prior sales were reported in the past three months, which limits visible selling trend data.

Corporate Governance Expert

TL;DR: Transaction appears consistent with routine option exercise and cashless settlement; disclosure meets Form 144 requirements.

The filing identifies the nature of acquisition as an employee stock option exercise with payment via broker cashless exercise, which is a standard liquidity mechanism for option holders. The document contains the seller's representation regarding undisclosed material information and notes no aggregated sales in the prior three months. Absent additional context on insider holdings or a trading plan, this disclosure is procedural rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	49407	1600641.00	43472928	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	08/12/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			49407	08/12/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Kiniksa (KNSA) report on Form 144?

The filing notifies a proposed sale of 49,407 Class A ordinary shares with an aggregate market value of $1,600,641.00 to be sold on 08/12/2025 on NASDAQ.

How were the Kiniksa shares acquired for the sale?

The shares were acquired on 08/12/2025 via an employee stock option exercise from Kiniksa Pharmaceuticals International, plc and settled by broker payment for cashless exercise.

Which broker is handling the proposed sale for KNSA?

The sale is to be handled by Charles Schwab & Co., Inc. (address listed in the filing).

Does the filing report other sales by this person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What representation does the seller make in the Form 144?

By signing the notice the seller represents they do not know of any material adverse information regarding the issuer that has not been publicly disclosed and may note any Rule 10b5-1 trading plan adoption date if applicable.